Despite repeated announcements of breakthroughs in Alzheimer's disease and related
dementias (ADRD) research, the stark reality remains that there have been no substantial
advancements in treatments. These failures in clinical translation are in large part
due to a systemic dependence on a flawed framework based on validating preclinical
findings using animal experimentation. In particular, researchers are repeatedly incentivized
by funding programs toward dominant reductionist frameworks (e.g., amyloid-, tau-centric)
and xenogenic research (e.g., transgenic and chimeric models). Here we present an
integrated program of impact studies, research protocols and policy proposals that
aim to address the stagnation in ADRD research, ethical issues and clinical outcomes
by advancing new multi-scale human-based approaches.
To read this article in full you will need to make a payment
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Alzheimer's & Dementia: The Journal of the Alzheimer's AssociationAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article Info
Publication History
P4-644
Identification
Copyright
© 2019 Published by Elsevier Inc.
